Author information
1Faculty of Dental Medicine and Health Osijek, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia.
2Faculty of Medicine Osijek, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia.
3Health Center Osijek-Baranja County, Osijek, Croatia.
4Department of Biology, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia.
5University Hospital Dubrava, Zagreb, Croatia.
6School of Medicine, University of Zagreb, Zagreb, Croatia.
7Microbial Biotechnology Department, Biotechnology Research Institute, National Research Center, Giza, Egypt.
8Egypt Center for Research and Regenerative Medicine (ECRRM), Cairo, Egypt.
9University of Connecticut Health Center, Farmington, CT, USA.
Abstract
Liver biopsy is historically the gold standard for liver fibrosis assessment of chronic hepatitis C patients. However, with the introduction and validation of noninvasive tests (NITs) to evaluate advanced fibrosis, and the direct-acting antiviral agents for treatment of chronic hepatitis C virus (HCV), the role of NITs have become even more complex. There is now need for longitudinal monitoring and elucidation of cutoff values for prediction of liver-related complication after sustained virological response. The aim of this report is to provide a critical overview of the various NITs available for the assessment of liver fibrosis in HCV patients.